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Abstract
Background: The topoisomerases Top1, Top2a and Top2b are important molecular targets for antitumor drugs, which
specifically poison Top1 or Top2 isomers. While it was previously demonstrated that poisoned Top1 and Top2b are subject
to proteasomal degradation, this phenomena was not demonstrated for Top2a.
Methodology/Principal Findings: We show here that Top2a is subject to drug induced proteasomal degradation as well,
although at a lower rate than Top2b. Using an siRNA screen we identified Bmi1 and Ring1A as subunits of an E3 ubiquitin
ligase involved in this process. We show that silencing of Bmi1 inhibits drug-induced Top2a degradation, increases the
persistence of Top2a-DNA cleavage complex, and increases Top2 drug efficacy. The Bmi1/Ring1A ligase ubiquitinates Top2a
in-vitro and cellular overexpression of Bmi1 increases drug induced Top2a ubiquitination. A small-molecular weight
compound, identified in a screen for inhibitors of Bmi1/Ring1A ubiquitination activity, also prevents Top2a ubiquitination
and drug-induced Top2a degradation. This ubiquitination inhibitor increases the efficacy of topoisomerase 2 poisons in a
synergistic manner.
Conclusions/Significance: The discovery that poisoned Top2a is undergoing proteasomal degradation combined with the
involvement of Bmi1/Ring1A, allowed us to identify a small molecule that inhibits the degradation process. The Bmi1/
Ring1A inhibitor sensitizes cells to Top2 drugs, suggesting that this type of drug combination will have a beneficial
therapeutic outcome. As Bmi1 is also a known oncogene, elevated in numerous types of cancer, the identified Bmi1/Ring1A
ubiquitin ligase inhibitors can also be potentially used to directly target the oncogenic properties of Bmi1.
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Introduction
Anticancer drugs targeting topoisomerases (Top) are some of
the most widely used chemotherapeutic agents. These drugs are
type specific; they target either Top1 or Top2a and Top2b. The
Top2 poisons (e.g. Etoposide, Teniposide (VM26) and Doxorubi-
cin) increase the steady state levels of an intermediate state of the
reaction, producing a Top2-DNA cleavage complex comprised of
Top2 covalently bound to a double strand DNA break [1].
Eventually the Top2-DNA cleavage complex forms cytotoxic
DNA lesions that trigger cell cycle arrest and cell death. Top2
poisons convert the enzyme into a DNA damaging agent with a
stochiometric relationship, one DNA double strand break for
every drug molecule bound to a Top2 enzyme. Thus sensitivity to
Top2 poisons is dependent on high levels of Top2-DNA cleavage
complexes. Moreover, the efficacy of Top2-targeted agents reflects
the persistence of drug-induced cleavage complexes in cells [2].
Proteasomal degradation of Top2 is one of the mechanisms that
decrease the persistence of drug-Top2-DNA complex thus
contributing to the emergence of drug resistance and reduced
efficacy. While Top2b was shown to be specifically degraded
followingtreatmentwith Top2 drugs[3,4],physiologicalconditions,
such as glucose deprivation and hypoxia, have been shown to
induce degradationofTop2a [5] leadingto decreasedTop2a levels,
rendering cells resistant to Top2-targeted drugs such as etoposide
and doxorubicin [6]. Hence, inhibition of ubiquitin-dependent
degradation of topoisomerases may improve long-term therapeutic
efficacy of topoisomerase-targeted drugs. Further support for a
degradation based resistance mechanism is obtained from the fact
that proteasome inhibition circumvents solid tumor resistance to
Top2-directed drugs [7]. Inhibition of the E3 ubiquitin ligase that
directsthedrug-Top-DNAcomplexfordegradationshouldstabilize
the cleavage complex in a similar manner and concomitantly
increase drug-induced efficacy. Inhibiting a specific E3 ligase is
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to have much lower side effects.
Here we demonstrate first that Top2a, similar to Top2b,i s
degraded following a treatment with the Top2 drug teniposide
(VM26) although at a slower rate then Top2b. We describe the
identification of Bmi1 and Ring1A as subunits of an E3 ubiquitin
ligase complex that is involved in both, drug-induced Top2a
degradationand low-glucoseinducedTop2a degradation.Silencing
of either Bmi1 or Ring1A by RNAi reduces drug-induced Top2a
degradation and correlates with increased drug efficacy in various
cell-lines, while overexpression of Bmi1 induces increased ubiqui-
tination ofTop2a. A purified complex formed byBmi1 and Ring1A
is shown to ubiquitinate immunopurified Top2a. We describe a
high-throughput assay for the discovery of small-molecule inhibitors
of Bmi1/Ring1A. A compound discovered using this assay prevents
degradation of Top2a induced by a Top2 drug and increases the
efficacy of Top2 drugs in a synergistic manner.
Materials and Methods
Reagents and Antibodies
All cell-lines were purchased from the American Type Culture
Collection (ATCC). Dicer substrate 27-nucleotide long siRNA
duplexes were purchased from IDT Integrated DNA technologies
(Coralville, IA). The sequences of the siRNA used are specified in
Table S1. All siRNA transfection were conducted using Saint-Red
siRNA transfection reagent (Synvolux Therapeutics, Groningen,
Holland) and all plasmid transfection were conducted using
Lipofectamine2000 reagent (Invitrogen, Carlsbad, CA). Tenipo-
side (VM26) was purchased from Alexis Biochemicals. Reagents
for homogenous time resolved FRET (HTRF
H) were purchased
from Cisbio Bioassays (Bagnols-sur-Ce `ze, France). For generation
of antibodies against Bmi1, a GST fusion protein containing
residues 228–326 of Bmi1 was constructed by PCR amplification.
The plasmid was expressed in E. coli BL21, purified by glutathione
chromatography, the GST removed by PreScission
TM (GE
Healthcare, Life Sciences) digest and sera produced in rabbits
(Sigma-Aldrich, Israel). Antibodies for Ring1A, Top1, Top2a and
Top2b were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Antibody for Ring1B was purchased from MBL
International (Woburn, MA). Chemical libraries were purchased
from IBS (Moscow, Russia), Chemdiv (San-Diego, CA) and
Timtec (Newark, Delaware).
Expression Plasmids
Human Bmi1 and Ring1A were PCR amplified from
I.M.A.G.E clones 4138748 and 6142438 respectively [I.M.A.G.E.
Consortium, http://image.llnl.gov [8], obtained from Geneservice
Ltd, UK]. Bmi1 was cloned into pcDNA3.1/V5-HisA (Invitrogen)
to include a C-terminal V5-HIS tag that was later modified to
include a C-terminal FLAG tag. Full length Top2a was generated
by combining two IMAGE clones (4101949 and 6501467) into
pCMV-SPORT6. HA-tagged ubiquitin was a gift from Prof. Yosef
Yarden, Weizmann Inst. of Science.
Recombinant Proteins
Ubiquitin activating enzyme E1 was expressed in Sf9 cells and
purified as previously described [9]. Various ubiquitin conjugating
enzymes and HA-ubiquitin, Biotin-ubiquitin and FLAG-ubiquitin
were purchased from Boston Biochem (Cambridge, MA). For
production of Bmi1 and Ring1A, codon optimized cDNAs
(DNA2.0) were cloned into pGEX-6P (GE Healthcare, Life
Sciences) in frame with Glutathione S-transferase (GST). The
Bmi1 fusion protein also contained an N-terminal V5 tag and a C-
terminal six-histidine tag. The Ring1A fusion protein also
contained an N-terminal HA tag and a C-terminal six-histidine
tag. For expression in E. coli BL21, proteins were induced with
0.2 mM IPTG and lysates were purified by sequential glutathione
(GE Healthcare, Life Sciences) and Ni-NTA (Qiagen, Valencia,
CA) chromatography.
Cell Viability Assay
Cells were plated at low confluence (about 10% for testing
compounds and 40% for siRNA assays) in 96-well plates. Twenty-
four hours later the cells were transfected with 100 nM siRNA or
treated with compounds and incubated for 72 hr. When testing
the effect of siRNA, thirty-two hours post-transfection the cells
were treated for 16 hours with DMSO or VM26 and then for
additional twenty-four hours with fresh medium. Viability was
measured using Cell Proliferation Reagent WST-1 (Roche,
Mannheim, Germany). LD50 was calculated using Prism software
(GraphPad software, CA).
VM26-Induced Top2a Degradation Assay
HeLa cells, either, two days post transfection with 100 nM
siRNA, or following one hour pre-treatment with the tested
compound, were treated with 100 mM VM26 for the indicated
time at 37uC. Where indicated, at the end of the incubation the
medium was replaced with fresh medium without drugs for 30
minutes to facilitate the recovery of ubiquitin and ubiquitin-like
non-conjugated Top2 from the DNA. Harvested cells were
resuspended in alkaline lysis buffer and treated with S7 nuclease
(Roche) as previously described [3]. The extracts were separated by
SDS-PAGE (7.5%) followed by Western-blot with Top2a antibody.
Top2a Cleavable Complex Detection
HeLa cells, two days after siRNA transfection, were treated with
VM26 (100 mM) with or without MG132 (50 mM) for 0, 0.5 or
6 hr. DNA bound proteins were separated as previously described
[10]. Samples of 1 mg DNA-protein complex were spotted on to a
PVDF membrane using a Dot-Blot apparatus and detected with
anti Top2a antibody.
In-Vivo Top2a Ubiquitination
HeLa cells transfected with plasmids encoding V5-tagged Bmi1
and Ring1A as indicated, were treated with 50 mM MG132 for 30
minutes with or without 100 mM VM26. The cells were extracted
with hot lysis buffer (1% SDS, 1 mM EDTA in PBS), boiled 5 min
at 95uC and sonicated to break DNA. The extracts were separated
by SDS-PAGE (6.5%) followed by immuno-detection with Top2a
antibodies.
In-Vivo Bmi1 Ubiquitination Assay
HeLa cells transfected with plasmids encoding V5-tagged Bmi1,
Ring1A and HA-tagged ubiquitin as indicated were treated for five
hours with either solvent or compound. Cells were harvested and
lysed in RIPA (50 mM Tris, pH 7.5; 150 mM NaCl; 1% NP-40,
0.5% Na-DOC, 0.1% SDS, 1 mM EDTA and a protease
inhibitor cocktail). Followed by three freeze-thaw cycles, Bmi1
was immunoprecipitaed using anti-V5 antibodies and separated by
SDS-PAGE (10%), followed by Western-blot with anti-HA
(ubiquitin) and anti-V5 (Bmi1) antibodies.
Gel Based Bmi1/Ring1A Ubiquitination Assay
Recombinant Bmi1, Ring1A or Bmi1/Ring1A complex
produced in bacteria were used in a cell free ubiquitination
reactions. Typical reaction contains 5 nM recombinant E1,
Bmi1/Ring1A Ligase Inhibitor
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buffer pH 7.6, 5 mM MgCl2, 2 mM ATP and 0.1 mM DTT.
Reaction was terminated after 60 minutes incubation at 37uC with
5 mM of EDTA, separated by SDS-PAGE (10%), followed
by Western-blot with anti-HA (Ring1A) and anti-V5 (Bmi1)
antibodies.
HTRF
H Based Bmi1/Ring1A Ubiquitination Assay
Ubiquitination reactions were as for the gel-based assay but
contained Flag-tagged ubiquitin. Ubiquitin-chain elongation was
quantified by HTRF
H (excitation at 320 nm, emission at 620 and
665) between adjacent Flag-ubiquitin molecules, using anti-Flag-
cryptate and anti-Flag-XL665 antibodies (CisBio) using a
dedicated fluorescence plate reader (RubyStar, BMG Labtech,
Offenburg Germany). Activity is calculated as the ratio of emission
of acceptor XL-665 (665 nm) to emission of the donor cryptate
(620 nm) X 10,000.
In Vitro Bmi1/Ring1A Mediated Top2a Ubiquitination
Assay
HeLa cells were transfected with Flag-tagged Top2a. Twenty-
four hours post transfection cells were harvested, extracted in lysis
buffer and immuno-precipitated with anti-Flag conjugated beads
(Sigma). The bead-bound proteins were used as a substrate in an
ubiquitination reaction, containing: recombinant Bmi1/Ring1A as
E3, UbcH5a as E2, E1, ATP and either biotin-tagged or HA-
tagged ubiquitin. At the end of the reaction beads were washed,
proteins eluted in SDS buffer (95uC, 5 min) and separated by
SDS-PAGE (6.5%), followed by detection with either streptavidin-
horseradish peroxidase (HRP) or anti-HA-HRP.
Immunofluorescence Assay
Cells (HeLa and A375) were fixed for 15 min in 4%
paraformaldehyde at ambient temperature, neutralized with
0.125 M glycine for 10 min, and then permeabilized with PBS,
0.1% Triton X-100 for 2 minutes, and washed three times with
PBS. Fixed cells were blocked with 10% normal donkey serum and
stained with Bmi1 sera using goat anti rabbit-cy2 as secondary
antibody. Cells were visualized using a confocal microscopy (Carl
Zeiss Axiovert 100 M).
Results
Teniposide Induces Proteasomal Degradation of Top2a
As it was reported that Top2a is proteasomally degraded under
physiological conditions such as low glucose and hypoxia [6], we
tested whether treatment with a Top2 drug can also lead to its
proteasomal degradation. To that end we treated cells with VM26
for up to 6 h and monitored the levels of both Top2a and Top2b
(Fig. 1). While Top2b levels decrease to bellow the detectable level
within 1.5 h, the decrease in the levels of Top2a is much slower,
with an estimated half-life of about 4 h. The degradation of both
Top2 isozymes, is prevented by the addition of the proteasome
inhibitor MG132, indicating that the degradation is proteasomal.
Identification of Bmi1 and Ring1A as an E3 Ubiquitin
Ligase Involved in Targeting Top2a-Drug Complex for
Degradation
To identify an E3 ubiquitin ligase responsible for targeting
Top2-drug complexes for degradation, we conducted an siRNA-
based screen. A list of 77 candidate E3 ligase genes was drawn
based on various criteria. The preliminary screen conducted in
HeLa cells was based on the assumption that silencing of a critical
E3 will increase the toxicity of a Top2-directed drug. The screen
was carried out in the presence of a sub-toxic concentration of
VM26. Cells were transfected separately with two different siRNA
per gene tested. Positive candidates that increased VM26 toxicity
were further tested for prevention of drug-induced Top2 (a or b
isoforms) degradation. Candidate targets that were positive in both
Figure 1. VM26 induces proteasomal degradation of Top2a. HeLa cells were treated for the indicated time with 100 mM VM26 and with
control solvent or 20 mM of proteasome inhibitor MG132. At the end of the incubation the medium was replaced with a fresh medium without drugs
for 30 minutes to facilitate the recovery of ubiquitin and ubiquitin-like non-conjugated Top2 from the DNA. Top2a and b proteins were recovered
from the DNA by alkaline lysis and S7 nuclease treatment and their level was determined by Western-blot with Top2a or b antibodies. The level of c-
Tubulin is shown as control.
doi:10.1371/journal.pone.0008104.g001
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additional siRNAs for the same target gene, so as to eliminate false
positive identification caused by siRNA off-target artifacts.
A single candidate, Bmi1, was scored positive in both the
increased toxicity assay and the drug-induced Top2a degradation
assay using two different siRNAs. Bmi1 is a RING finger protein
and is a key component of the Polycomb repressive complex 1
(PRC1) that is involved in epigenetic silencing of targeted genes
[11]. Three different siRNAs designed to knockdown Bmi1
expression were assayed for their effect on VM26-induced toxicity
in HeLa cells (Fig. 2A). Two of the siRNAs (X63 and X165)
sensitized the cells for VM26-induced toxicity, increasing the
killing efficacy of VM26 by 50–60%, whereas the third (X164) had
no effect. When testing the effectiveness of the three siRNAs
towards reducing the expression level of Bmi1 protein, we found
that X164, the only siRNA that failed to increase the efficacy of
VM26, also failed to reduce expression of Bmi1 protein (Fig. 2A
lower panel).
We further examined the effect of Bmi1 silencing on drug-
induced degradation of the two Top2 isozymes (a or b). HeLa cells
transfected with Bmi1 siRNAs were treated for the indicated time
with VM26. At the end of the treatment, the total amount of Top2
proteins was determined. The results show that both siRNA that
are effective at reducing Bmi1 protein level, X63 and X165,
prevented the drug-induced Top2a degradation (Fig. 2B). Silenc-
ing of Bmi1 did not prevent VM26-dependent degradation of
Top2b (Fig. 2C).
Bmi1 Silencing Increases DNA-Top2a Cleavage Complex
Level
Drug-induced cell toxicity is considered to be in correlation with
the amount of the DNA-Top cleavage complex [2] and our
hypothesis was that stabilization of this complex would lead to
increased drug efficacy. We set out to check if silencing of Bmi1
also stabilizes the fraction of Top2a that is covalently bound to
DNA. HeLa cells transfected with either control or Bmi1 siRNA
were treated for various periods of time with either DMSO or
VM26 with or without the proteasome inhibitor MG132 as
indicated (Figure 2D). Genomic DNA was separated on a cesium-
chloride cushion to resolve proteins covalently bound to DNA
from free proteins. The pelleted genomic DNA was recovered and
the amount of Top2a covalently bound to equal amounts of DNA
determined by a dot-blot analysis. In DMSO treated cells Top2a
was not found attached to the DNA. After 30 minutes of VM26
treatment, Top2a was found attached to DNA in both control cells
and cells with reduced expression of Bmi1. In the control cells
Figure 2. Silencing of Bmi1 increases Top2-drug-induced toxicity, inhibits drug-induced Top2a degradation and stabilizes Top2a
cleavage complex. A. HeLa cells were transfected with three different siRNAs targeting Bmi1 (X63, X164, X165) and scramble siRNA (SC). Following
transfection, the sensitivity to 1 mM VM26 was determined as described in the material and methods. Lower panel: Immuno-blot assay to determine
the reduction of Bmi1 protein level. B. HeLa cells transfected with siRNA as described in panel A were treated 48 hours later with VM26 for the
indicated time. Top2a protein was recovered from the DNA by alkaline lysis and S7 nuclease treatment and its level was determined by Western-blot
with Top2a antibody. Levels of Top1 are shown as control. C. HeLa cells transfected with control or Bmi1 siRNA (X63) were treated 48 hours later with
100 mM VM26 and 25 mM MG132 for 3 hours as indicated. The level of Top2b was determined after alkaline lysis and S7 nuclease treatment by
Western-blot with Top2b antibody. Levels of Top1 are shown as control. D. HeLa cells transfected with control (SC) or Bmi1 siRNA (X63) were treated
48 hours later with VM26 (100 mM) and MG132 (25 mM) as indicated. The level of Top2a cleavage complex in the cells was determined as described in
the material and methods.
doi:10.1371/journal.pone.0008104.g002
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treatment, while this elimination is prevented by MG132,
indicating it was degraded by the proteasome. In contrast, in
Bmi1 knockdown cells the Top2a-DNA complex is stabilized, as it
is found bound to genomic DNA also after 6 hours of drug
treatment. This result strengthens the hypothesis that silencing of
Bmi1 increases drug efficacy thorough stabilization of the
cytotoxic Top2a-DNA cleavage complex.
Bmi1 Silencing Increases Drug Efficacy by an Order of
Magnitude
To evaluate better the degree by which Bmi1 silencing increases
the sensitivity to Top2 drugs we determined the LD50 of VM26 in
different cell lines transfected with Bmi1 or control siRNAs. In
HeLa cervical cancer cells an LD50VM26 of 0.3 mM was measured
with Bmi1 siRNA compared to 3.5 mM with a control siRNA, and
in A549 lung cancer cells an LD50VM26 of 1.1 mM was measured
with Bmi1 siRNA compared to 7.4 mM with the control siRNA. In
both cases, Bmi1 silencing increases the efficacy of VM26 about
ten-fold (Fig. 3). Similar results were obtained with HT29 colon
cancer cell-lines (data not shown). The effect in MDA-MB-231
breast cancer cells was somewhat weaker, LD50VM26 of 3.9 mM
with Bmi1 siRNA compared to 7.2 mM with control siRNA
(Fig. 3). Silencing of Bmi1 in many other cells such as PC3 and
DU145 prostate, MDA-MB 468 breast and RKO colon cancer
cell lines had by itself a strong toxic effect (data not shown) that
hindered testing sensitization to the drug. This death may be
related to a pro-malignant function of Bmi1, as indeed it was
reported that silencing of the Bmi1 expression promotes cancer-
specific cell death [12].
Silencing of Bmi1 Prevents Glucose Deprivation Induced
Top2a Degradation
Previous publications show that Top2a level is reduced at
physiological conditions such as glucose deprivation and hypoxia
that are common in the tumor environment, and that this leads to
decreased efficacy of the Top2-directed drugs [6]. The reduction
in Top2a level is due to its increased proteasomal degradation,
[7,13,14]. This led us to test whether Bmi1 silencing can prevent
the low-glucose-induced Top2 degradation. Towards that end,
HeLa (Fig. 4A) or HT29 (Fig. 4B) cells treated with either control
or Bmi1 siRNA were grown for two days in either normal or low
glucose media. In the control siRNA treated cells, the level of
Top2a was reduced when cells were grown in low-glucose, while
in cells transfected with Bmi1 siRNA there was no change in the
levels of Top2a. These results suggest that silencing of Bmi1 has
the potential to also prevent Top2-directed drug resistance
emerging from reduction of Top2a level due to conditions such
as glucose starvation.
Silencing of Ring1A Prevents Drug-Induced Top2a
Degradation
Bmi1 is a component of PRC1 [15] that is involved in Histone
2A (H2A) ubiquitination [16,17]. PRC1 also contains the
interchangeable RING finger proteins, Ring1A and Ring1B that
bind to Bmi1 through their RING domains [18,19,20]. Therefore,
to further characterize the Bmi1 E3 complex we tested the role of
Ring1A and Ring1B in drug-induced Top2a degradation using an
RNAi approach in HeLa cells. Verified siRNAs for Ring1A and
Ring1B (Figure 5, lower panels) were tested for their effect on
VM26-induced Top2a degradation (Figure 5 upper panel). The
results demonstrate that while reduction of Ring1A expression
prevented drug induced Top2a degradation to the same extent as
Figure 3. Increased toxicity of VM26 following siRNA mediated
reduction of Bmi1. HeLa, A549 and MDA-MB-231 cells were
transfected with Control (SC) or Bmi1 (X63) siRNAs. Following
transfection, the sensitivity of the cells to different concentrations of
VM26 was determined as described in material and methods. The LD50
of VM26 was calculated using Prism software (see text). The reduction
of Bmi1 protein level by the siRNA is presented in the insert.
doi:10.1371/journal.pone.0008104.g003
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had no effect. These results, together with the known interaction
between Bmi1 and the two Ring1 proteins, suggest that Bmi1 and
Ring1A form an E3-ubiquitin ligase involved in drug-induced
Top2a degradation. It is interesting to note that Ring1B and not
Ring1A is the catalytic subunit for PRC1 mediating ubiquitination
of H2A [16] while both Bmi1 and Ring1A increase the
ubiquitination efficacy of Ring1B [17].
Bmi1 and Ring1A Form Together an Active E3 Ubiquitin-
Ligase that Binds and Ubiquitinates Top2a
Next, we wanted to characterize the ubiquitination activity of
Ring1A and Bmi1. For that purpose we produced tagged
recombinant Ring1A and Bmi1 proteins and tested their activity,
either separately or together, in a cell-free auto-ubiquitination
assay with a panel of different E2 ubiquitin-conjugating enzymes.
Ubiquitination activity is assessed by monitoring the increase in
molecular weight of the ubiquitinated proteins, using tag-directed
antibodies. When each protein is assayed alone, Ring1A acts
preferentially with UbcH5a (Fig. 6A upper panel), while Bmi1 is
inactive with all the E2 enzymes tested (Fig. 6A lower panel).
When Ring1A and Bmi1 are combined and assayed together,
Bmi1 is highly ubiquitinated in the presence of UbcH5a (Fig. 6B
lower panel) whereas ubiquitination of Ring1A is very weak
(Fig. 6B upper panel). Weak Bmi1 ubiquitination is also seen with
UbcH2, UbcH5b, UbcH5c and UbcH6. The preference of Bmi1/
Ring1A E3 ubiquitin-ligase to UbcH5a was confirmed using the
HTRF
H-based detection method of cell-free ubiquitin-chain
elongation (Fig S1). This assay measures total ubiquitination
activity regardless of the ubiquitination target. The results of the
HTRF
H-based assay are in agreement with the gel-based assay
showing that the Bmi1-Ring1A complex has a preference for
UbcH5a as an E2. Using this type of assay we also confirmed the
gel-based results that Ring1A alone has weak ubiquitination
activity, Bmi1 alone is inactive while assaying Bmi1 and Ring1A
together results in significant increase in the activity (Fig. 6C).
There are two possible explanations for the observed ubiqui-
tination of Bmi1 when it is assayed together with Ring1A (Fig. 6B
and 6C). One explanation is that ubiquitination of Bmi1 is
Figure 4. Effect of Bmi1 silencing on Top2a protein levels in
glucose deprived cells. HeLa (A) and HT-29 cells (B) were transfected
with either control (SC) or Bmi1 siRNA and then grown in normal
medium (+Gluc) or in medium without glucose (w/o Gluc) for additional
twenty-four hours. The levels of Top2a,T o p 1a n dB m i 1w e r e
determined by Western-blot analysis.
doi:10.1371/journal.pone.0008104.g004
Figure 5. Ring1A but not Ring1B is required for VM26 induced degradation of Top2a HeLa cells transfected with siRNA targeting
Bmi1, Ring1A, Ring1B or control siRNA (SC) were treated 48 hours later with 100 mM VM26 for the indicated time. Top2a protein was
recovered from the DNA by alkaline lysis and S7 nuclease treatment and its level was determined by Western-blot with Top2a antibody. Levels of
Top1 are shown as control. The activity of Ring1A and Ring1B targeting siRNAs was verified by Western-blot analysis with the appropriate antibodies
(lower panels).
doi:10.1371/journal.pone.0008104.g005
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PLoS ONE | www.plosone.org 6 December 2009 | Volume 4 | Issue 12 | e8104Figure 6. Characterization of Bmi1 and Ring1A ubiquitination activity in cell-free systems. Cell-free ubiquitination assays were carried
with recombinant Bmi1 and Ring1A proteins and with different recombinant E2s. Levels of ubiquitination were determined by Western-blot analysis
with indicated antibodies (A&B) or by HTRF
H method (C & D). A. Ubiquitination reactions with either Ring1A (top) or Bmi1 (bottom) and with different
E2 enzymes. B. Ubiquitination reactions containing both Bmi1 and Ring1A, with different E2 enzymes. Western-blot was carried out for tag present on
either Ring1A (top) or Bmi1 (bottom). C. Ubiquitin-chain elongation assay carried out with recombinant Bmi1 and Ring1A proteins, either separately
or in combination, using UbcH5a as an E2. D. Ubiquitin-chain elongation assay carried out with either a wild-type GST-Bmi1/Ring1A purified complex
or purified complexes with different combinations of RING domain mutants. A reaction containing Bmi1 only serves as a background control. The E2
enzyme utilized is UbcH5a.
doi:10.1371/journal.pone.0008104.g006
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binding to Ring1A activates Bmi1 to become an active E3
ubiquitin ligase. To distinguish between these two possibilities we
carried the HTRF
H-based ubiquitin-chain elongation assay with
wild-type or L20A RING domain mutant of Bmi1 and either wild-
type Ring1A or a I50A RING domain mutant of Ring1A. The
L20A and I50A point mutations in Bmi1 and Ring1A respectively,
are similar to mutations in other RING proteins where it was
demonstrated to prevent binding to the E2 [21,22,23], but does
not interfere with functional dimerization with a partner RING
domain protein [24]. Strong ubiquitination activity is detected
only when Bmi1, wild-type or mutant, are combined with
functional Ring1A (Fig. 6D). When Bmi1 is combined with the
I50A Ring1A mutant protein, the complex is inactive (Fig. 6D),
indicating that binding of Ring1A is not sufficient for Bmi1 to
become active. The activity of Bmi1(L20A)-Ring1A complex was
comparable to the activity of wild-types Bmi1-Ring1A complex
suggesting that the E2 binding site on Bmi1 is not contributing to
the activity. Hence, we conclude that Bmi1 and Ring1A form an
active heterodimeric E3 ubiquitin ligase, where Ring1A is the
active component and Bmi1 greatly enhances its activity.
To determine the effect of Bmi1 and Ring1A on Top2a
ubiquitination in cells we transfected HeLa cells with Bmi1 and
Ring1A separately or together. Cells were then treated with VM26
to induce Top2a ubiquitination and MG132 to prevent protea-
somal degradation, and allow the accumulation of ubiquitinated
Top2a species (Fig. 7A). We show that overexpression of Bmi1 is
sufficient to increase the ubiquitination of Top2a, while Ring1A
overexpression does not contribute additional ubiquitination. This
suggests that Bmi1 is the limiting factor in Top2a ubiquitination in
HeLa cells and is in agreement with various reports showing that
Bmi1 is a key factor in the PRC1.
Next, to establish whether Bmi1 and Ring1A are capable of
binding Top2a directly, we tested the binding of recombinant
Bmi1 and Ring1A to recombinant Top2a. Binding reactions were
set up with varying protein combinations. Top2a was immuno-
precipitated with anti-Flag beads and attached proteins were
detected by immuno-blot (Fig. 7B). Both Bmi1 and Ring1A are
Figure 7. Bmi1 and Ring1A bind and ubiquitinate Top2a. A. HeLa cells were transfected with Ring1A and V5-tagged Bmi1 as indicated, and
treated with 50 mM MG132 for 30 minutes with or without 100 mM VM26. The cells were extracted by hot lysis followed by sonication. Proteins were
separated by 6.5% SDS-PAGE and Top2a was detected by Western-blot. The levels of transfected Bmi1 and Ring1A in the total extracts were detected
using the indicated antibodies. B. Recombinant GST-myc-Bmi1 and GST-HA-Ring1A were incubated with or without recombinant FLAG-Top2a. At the
end of the incubation Top2a was immuno-precipitated with anti-Flag conjugated beads and the bound proteins were detected by Western-blot as
indicated in the figure. C. Flag-tagged Top2a was transfected into HeLa cells. Cell extracts were immuno-precipitated with anti-Flag conjugated
beads. The immuno-precipitate was used as a substrate in an ubiquitination reaction, using recombinant Bmi1/Ring1A, UbcH5a and biotin-tagged
ubiquitin. At the end of the incubation the beads were washed, the bound proteins were separated on 6.5% SDS-PAGE and blotted with streptavidin-
tagged HRP.
doi:10.1371/journal.pone.0008104.g007
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each one was added separately or when combined together. To
test if Top2a is a direct ubiquitination target of Ring1A-Bmi1, we
used Flag-tagged Top2a immunopurified from transfected HeLa
cells as a substrate in a cell-free ubiquitination assay containing
biotin-tagged ubiquitin, UbcH5a and Bmi1/Ring1A. At the end
of the reaction Top2a bound to anti-Flag was washed extensively
and resolved by SDS-PAGE and ubiquitinated forms were
detected with Streptavidin-HRP (Fig. 7C). The results show that
Top2a is efficiently ubiquitinated by the Bmi1/Ring1A E3
complex in a cell-free assay. These results together with the
stabilization effect of Bmi1 and Ring1A siRNAs on drug-induced
Top2a degradation, suggest that the Bmi1/Ring1A complex may
function as a Top2a ubiquitin ligase.
Identification of Bmi1/Ring1A Inhibitors
After identifying Bmi1/Ring1A, as an E3 ligase involved in
drug-induced Top2a degradation, we initiated a campaign for the
identification of small-molecule inhibitors of its ubiquitination
activity. The assumption is that such inhibitors will diminish
proteasomal degradation of Top2a thus increasing the potency of
Top2 directed drugs. For this purpose, we modified the HTRF
H-
based Bmi1/Ring1A ubiquitination assay into high throughput
format. Using this assay we screened a library of 56,000 diverse
small-molecule compounds and identified several chemical
structural families that inhibit Bmi1/Ring1A ubiquitination
activity. Initial hits were tested using several cell-free filtering
assays, designed to eliminate assay artifacts and inhibitors of other
components in the reaction. Specifically we set up assays for
measuring E1 dependent ubiquitin activation and E2 dependent
ubiquitin conjugation. Bmi1/Ring1A inhibition was also mea-
sured using a gel-based method similar to that shown in figure 6B
(data not shown).
Following elimination of false positive hits, four different
chemical scaffolds were identified. One of them is the Indan-1,3-
dione family. Four compounds of this family were identified in the
screen. Here we describe the results with one of these compounds,
PRT4165 (Fig. 8A), that has an IC50 of 3.9 mM in the cell-free
HTRF
H assay (Fig. 8B). In order to verify that the activity of
PRT4165 is not an HTRF artifact, its activity was also tested by a
Western-blot based ubiquitination assay (Fig. 8C), an assay that
uses a completely different readout. The results of the gel-based
assay demonstrate that the inhibition by PRT4165 is not
dependent on the detection system. At 12.5 mM PRT4165
shortening of the ubiquitin chains is observed and at 25 mM
ubiquitination is nearly completely eliminated. Next we tested if
the inhibition of Bmi1/Ring1A ubiquitination activity is translated
into inhibition of Bmi1/Ring1A dependent Top2a ubiquitination,
in a cell-free system (Fig. 8D). We show that indeed PRT4165 also
inhibits Bmi1/Ring1A mediated ubiquitination of Top2a.
Cellular Activity of the Bmi1-Ring1A Inhibitor PRT4165
In order to test if PRT4165 inhibits Bmi1/Ring1A activity also
in the context of a whole cell, we tested its effect on Bmi1/Ring1A
self-ubiquitination activity in HeLa cells. The assay measures
Ring1A dependent Bmi1 ubiquitination with exogenously ex-
pressed proteins. When Bmi1, Ring1A and HA-tagged ubiquitin
are co-transfected into HeLa cells, conjugation of HA-ubiquitin to
immunoprecipitated Bmi1 is observed (Fig. 9A). Treating cells for
5 h with 50 mM PRT4165 inhibits this ubiquitination. We
assumed that PRT4165 inhibition of Bmi/Ring1A will not be
limited to self-ubiquitination but will also inhibit VM26-induced
Top2a ubiquitination and thus its proteasomal degradation.
Toward that aim, HeLa cells were treated with either solvent or
50 mM PRT4165 combined with VM26 for the indicated periods
(Fig. 9B). The total level of Top2a in the cells was determined after
nuclease treatment. After 4 h of VM26 treatment, Top2a is mostly
degraded, whereas 50 mM PRT4165 completely inhibits this
VM26-induced degradation.
Bmi1 is reported to appear partly in diffuse nuclear staining and
partly as nuclear speckles indentified as polycomb-group (PcG)
bodies [25]. The localization of Bmi1 to the PcG bodies is
dynamic and it was suggested that post-translational regulation
such as phosphorylation or ubiquitination may be involved [25].
This led us to test whether PRT4165 affects Bmi1 localization in
cells. Staining of cells with Bmi1 antibodies, results in a typical
punctate appearance of endogenous Bmi1 (Figure 9C). We found
that a 3 hour treatment with 50 mM PRT4165 in A375 cells or
100 mM in HeLa cells, leads to disappearance of the speckled
staining in the nuclei and appearance of Bmi1 also in the
cytoplasm (Figure 9C).
PRT4165 Synergistically Increases Potency of Top2 Drugs
Next we set to test whether prevention of drug-induced Top2a
degradation by PRT4165 is also translated into increased Top2
drug efficacy in these cells. Towards that end, we determined the
effect of PRT4165 on the LD50 of VM26 in A549 lung cancer
and A375 melanoma cells (Fig. 10A). Increasing concentrations of
PRT4165 systematically improves the efficacy of VM26 in a dose-
dependent manner. In A549 lung cancer cells (top panel) the
LD50 of VM26 is reduced ten-fold from 3.1 mM when treated
alone to 0.3 mM when VM26 is combined with 33 mMo f
PRT4165. In A375 melanoma cells (bottom panel) PRT4165 is
even more effective, a similar ten-fold increase in VM26 efficacy is
observed at a concentration of 5.5 mM PRT4165. Isobolgram
analysis (Fig. 10B) demonstrates that the combined toxicity of
PRT4165 and VM26 is synergistic (top panel) whereas the
combined effect of PRT4165 with another commonly used cancer
drug such as Taxol, that does not target topoisomerases, is additive
(Fig. 10B, bottom panel). The synergistic effect PRT4165 is not
limited to VM26 alone, but is observed also with other Top2 drugs
such as doxorubicin (data not shown).
Discussion
Here we describe, first the identification of Bmi1/Ring1A as a
functional ubiquitin-ligase complex involved in Top2a degrada-
tion induced by either Top2 drugs or low glucose, and then the
discovery of a small molecular weight inhibitor for this ligase. We
show that Top2a is an ubiquitination target of Bmi1/Ring1A in a
cell free system and that Bmi1 overexpression increases drug-
induced Top2a ubiquitination in cells. Recently it was reported
that the polycomb complex remains bound to DNA during DNA
replication in vitro [26]. This localizes the polycomb complex at
the right place and time to be a direct E3 ligase of Top2a when it
is within the Top-DNA cleavage complex. However, whether or
not Top2a is indeed a direct ubiquitination target of Bmi1/
Ring1A also in cells still has to be shown by additional studies.
Two other E3 ubiquitin ligases, Mdm2 and Brca1, were
implicated in the ubiquitination and degradation of Top2a.
Mdm2 binds to Top2a and mediates its ubiquitination and
subsequent degradation following etoposide treatment [27]. Cells
harboring a single nucleotide polymorphism that increase the
expression of Mdm2 were found to be about ten-fold more
resistance to Top2 poisons whereas silencing of Mdm2 increased
sensitivity, although to a lesser extent. Several pieces of evidence
connect Brca1 to Top2a ubiquitination. It was shown that Brca1
binds and ubiquitinates Top2a and this ubiquitination increases
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was suggested that retinoblastoma protein (pRb) facilitates
processing and repair of Top2-cleavable complexes by recruiting
Brca1 to Top2a at the damaged site [29]. Oxidative stress also
leads to Brca1 and pRb-dependent ubiquitination and subsequent
degradation of Top2a in some cell lines [30]. The last two reports
suggest that pRb serves as an adaptor protein to recruit Brca1
(and other proteins) involved in Top2a ubiquitination. Interest-
ingly, pRb is also localized in the PcG bodies and interacts with
Ring1A [31]. The exact roles filled by Mdm2, Brca1 and Bmi1/
Ring1A, in the ubiquitination and degradation of Top2a is yet to
be determined.
Self-ubiquitination is a mechanism that serves some E3-ligases
as a mean to control their own level. Inhibiting Bmi1/Ring1A
ubiquitination activity may raise the concern that this may lead to
increased cellular levels of these oncogenic proteins. Prior to
initiating the screen for inhibitors, we have noticed that co-
expression of Bmi1 and Ring1A results in higher expression levels
of both proteins (unpublished results). These results imply that the
self-ubiquitination activity of Bmi1/Ring1A is not serving as a
Figure 8. Compound PRT4165 inhibits both Bmi1/Ring1A self-ubiquitination and Top2a ubiquitination in-vitro. A. Chemical structure
of PRT4165. B. Inhibition of Bmi1/Ring1A self-ubiquitination as detected by HTRF
H assay and determination of IC50 value. C. Inhibition of Bmi1-Ring1A
self-ubiquitination by PRT4165 as detected by a Western-blot method. D. Inhibition of Bmi1/Ring1A-induced ubiquitination of immunopurified FLAG-
Top2a. HeLa cells were transfected with FLAG-Top2a or empty vector. Twenty-four hours post transfection Top2a was immunopurified on anti-FLAG
beads and used as a substrate for ubiquitination with recombinant Bmi1/Ring1A.
doi:10.1371/journal.pone.0008104.g008
Bmi1/Ring1A Ligase Inhibitor
PLoS ONE | www.plosone.org 10 December 2009 | Volume 4 | Issue 12 | e8104degradation signal, similar to the reported results for Bmi1 and
Ring1B [24]. In agreement with this, it turns out, that the
identified inhibitor PRT4165 does not increase the observed
cellular levels of either Bmi1 or Ring1A (data not shown).
However, application of PRT4165 does modify the cellular
localization of Bmi1, from discrete PcG bodies within the
nucleolus to disperse nuclear and even cytoplasmic localization.
How the inhibitor leads to miss-localization of Bmi1 and whether
it affects the oncogenic properties of Bmi1 remains to be explored.
Previous publications have demonstrated ubiquitination activity
of Ring1A [19,32] however this activity was very weak and the
main ubiquitination activity of the PRC1 complex was attributed
to Ring1B. Here we demonstrated a robust ubiquitination activity
of Ring1A when it is in a complex with Bmi1. It appears that the
contribution of Bmi1 does not depend on the integrity of its E2
binding site. An activation role of Bmi1 was also demonstrated in
the case of Ring1B-dependent H2A ubiquitination [17,24,32].
Bmi1 has a key role in the function of the PRC1 complex as was
reflected by its overexpression in many different tumors. In
agreement, we show that Bmi1 overexpression, but not Ring1A
overexpression, increases drug-induced Top2a ubiquitination.
Taken together it may suggest that a key role of Bmi1 in the
PRC1 complex is to activate the ubiquitination activity of PRC1 in
a Ring1A or a Ring1B-dependent manner. In addition it may
suggest a modular mode of action, where the level of activity is
determined by the expression of Bmi1, and the relative levels of
the other RING-domain subunits influence the target selectivity.
Bmi1 is a key component of PRC1 regulating chromatin
remodeling and gene expression pathways essential for self-
renewal of stem cells and cancer stem cells [33,34,35,36]. Bmi1
was first identified as an oncogene inducing B and T cell leukemias
[37,38] and later it has been repeatedly shown to be highly
overexpressed in various cancer cell-lines and tumors (reviewed in
[39,40]). Moreover, silencing of Bmi1 by siRNA leads to the death
of cancer cells specifically [12], suggesting that its activity is also
essential for viability during the malignant stage. Ring1A has been
also shown to have tumorogenic properties as its overexpression
leads to anchorage-independent growth and tumor induction in
athymic mice [18], however its expression does not seem to be
upregulated in tumors [41]. In contrast, Ring1B expression is
increased in various types of tumors [41]. The PRC1 complex
with its core activity of an ubiquitin ligase, cooperates with the
PRC2 complex, with a core activity of histone methyltransferase
[42] and association with DNA methyltransferases (DNMTs)
activity [43]. A key component in the PRC2 complex is EZH2
histone methylase and similar to Bmi1, it is also elevated in various
cancers [42]. PRC1 and PRC2 act together to epigenetically
silence target genes [44], many of them with pro-differentiation
and anti-proliferative function [45]. The exact role of the different
polycomb complexes, the relation between the methylation and
ubiquitination and the sequence of events are under extensive
research by many labs. However, the picture that emerges is that
these complexes and their activities play a crucial role in the
initiation and maintenance of cancer and stem cell phenotype of
cancer cells. Hence, the ubiquitination and methylation activities
of the polycomb complexes appear as promising therapeutic
targets for cancer therapy and moreover, for targeting cancer-
stem-cell self-renewal. Therefore, the effect of PRT4165 on the
PRC1-repressed genes and the self-renewal capabilities of cancer
stem cells would be highly relevant to its therapeutic potential.
Inhibiting Bmi1/Ring1A is expected to increasethe persistence of
Top2a-DNA cleavage complex, by preventing its proteasomal
degradation, leading to increased potency of Top2 drugs. Such a
combination therapy can be beneficial, as increasing the potency of
sucha drug bythismechanism,can eitherachieve bettereradication
of cancer cells using the same amount of drug, or allow the use of
lower doses. This can reduce some of the side effects associated with
these cytotoxic drugs. As Top2a is expressed only in proliferating
cells [46] and is overexpressed in many cancer cells, a combination
Figure 9. In-vivo activity of PRT4165. A. Inhibition of Bmi1
ubiquitination. HeLa cells were transfected with Bmi1-FLAG, Ring1A and
HA-ubiquitin. Twenty-four hours post transfection the cells were treated
with either solvent (0.5% DMSO, 0.5% PEG400) or 50 mM PRT4165 for
5 hours. Bmi1-FLAG was immunoprecipitated from cell lysates, and
conjugated ubiquitin was detected by Western-blot with anti-HA
antibody. B. Prevention of Top2a drug induced degradation. HeLa cells
were treated with 100 mM and with either 50 mM PRT4165 or solvent for
theindicatedtime.Top2aproteinwasrecoveredfromtheDNAbyalkaline
lysis and S7 nuclease treatment and its level was determined by Western-
blot with Top2a antibody. C. Disruption of Bmi1 nuclear localization.
CellularlocalizationofBmi1wasdeterminedbyimmunoflouresenceusing
Bmi1 directed antibodies in HeLa and A375 cells, treated for 3 hours with
the indicated concentrations of PRT4165 or solvent.
doi:10.1371/journal.pone.0008104.g009
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expected to achieve similar specific killing of cancer cells through
increased poisoning of Top2a, with reduced unwanted side effects.
The ubiquitin system of protein modification is a crucial
mechanism involved in almost every aspect of cellular processes.
The evidences for the involvement of the ubiquitin system in
human diseases are rapidly accumulating reflecting the central role
of the system in cellular function. However, the concept that E3
ubiquitin ligases are druggable targets is still to be demonstrated.
The complexity of the assays and the lack of classic enzymatic
activity make the task even more challenging. Bmi1 represents one
of the attractive potential targets in the ubiquitin system, either for
a stand-alone therapy or as we show here, for combination therapy
with Top2 poisons.
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